Cost-effectiveness of prevention of coronary disease in Germany

被引:0
|
作者
Lauterbach, KW [1 ]
Gerber, A [1 ]
Klever-Deichert, G [1 ]
Stollenwerk, B [1 ]
机构
[1] IGKE, D-50935 Cologne, Germany
来源
关键词
coronary heart disease; cost-effectiveness; prevention; risk factor;
D O I
10.1007/s00392-005-1314-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is generally accepted that the incidence of coronary heart disease can effectively be reduced by strengthening prevention. At the same time, it is still unclear how large the effects of life-style oriented preventive measurements such as diet and exercising are in everyday life. Furthermore, there is an ongoing debate on what measurements are effective. Thus, against the background of dwindling financial resources in health care the input of health economic evaluation is explicated. General issues of health economic evaluation are presented. After that, an overview on the current findings of cost-effectiveness in primary prevention of coronary heart disease is given. Risk factors are separately discussed. It is demonstrated that preventive measurements dealing especially with hypertension and hypercholesterolemia can be cost-effective.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 50 条
  • [1] Cost-effectiveness of Pravastatin in secondary prevention of coronary artery disease
    Ashraf, T
    Hay, JW
    Pitt, B
    Wittels, E
    Crouse, J
    Davidson, M
    Furberg, CD
    Radican, L
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04): : 409 - 414
  • [2] A concise review of the cost-effectiveness of coronary heart disease prevention
    Brown, AID
    Garber, AM
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (01) : 279 - +
  • [3] Cost-effectiveness of aspirin for the primary prevention of coronary heart disease
    Rodondi, Nicolas
    Moran, Andrew
    Coxson, Pamela G.
    Lightwood, James
    Williams, Lawrence W.
    Cornuz, Jacques
    Goldman, Lee
    [J]. CIRCULATION, 2006, 114 (18) : 827 - 827
  • [4] PRIMARY PREVENTION OF CORONARY HEART-DISEASE IN THE FEDERAL-REPUBLIC-OF-GERMANY ANALYSIS OF COST-EFFECTIVENESS
    ASSMANN, G
    SCHULTE, H
    [J]. DRUGS, 1990, 40 : 33 - 37
  • [5] Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan
    Nagata-Kobayashi, S
    Shimbo, T
    Matsui, K
    Fukui, T
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 104 (02) : 213 - 223
  • [6] Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada
    Riviere, M
    Wang, SS
    Leclerc, C
    Fitzsimon, C
    Tretiak, R
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (07) : 991 - 997
  • [7] Comparative cost-effectiveness of interventions for the primary prevention of coronary heart disease
    Lim, SS
    Vos, TE
    Begg, S
    Liew, D
    Peeters, A
    McNeil, JJ
    [J]. CIRCULATION, 2002, 106 (19) : 758 - 759
  • [8] The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease
    Gillespie, Paddy
    O'Shea, Eamon
    Murphy, Andrew W.
    Byrne, Mary C.
    Byrne, Molly
    Smith, Susan M.
    Cupples, Margaret E.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2010, 26 (03) : 263 - 271
  • [9] COST-EFFECTIVENESS OF ASPIRIN IN SECONDARY PREVENTION OF CORONARY HEART-DISEASE
    GASPOZ, JM
    GOLDMAN, P
    WILLIAMS, L
    WEINSTEIN, M
    GOLDMAN, L
    [J]. CIRCULATION, 1995, 92 (08) : 219 - 219
  • [10] Cost-effectiveness of statins for primary prevention of coronary heart disease in Japan
    Ikeda, Shunya
    Kobayashi, Makoto
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S225 - S226